New York Life Investment Management LLC Raises Stock Position in Eli Lilly and Company (NYSE:LLY)

New York Life Investment Management LLC increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 0.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 126,377 shares of the company’s stock after purchasing an additional 836 shares during the quarter. Eli Lilly and Company makes up 0.8% of New York Life Investment Management LLC’s portfolio, making the stock its 26th biggest holding. New York Life Investment Management LLC’s holdings in Eli Lilly and Company were worth $73,668,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in LLY. Vicus Capital increased its holdings in shares of Eli Lilly and Company by 78.6% in the third quarter. Vicus Capital now owns 977 shares of the company’s stock worth $525,000 after purchasing an additional 430 shares during the last quarter. Callahan Advisors LLC increased its stake in Eli Lilly and Company by 655.2% in the 3rd quarter. Callahan Advisors LLC now owns 7,779 shares of the company’s stock worth $4,178,000 after acquiring an additional 6,749 shares during the last quarter. Live Oak Private Wealth LLC boosted its stake in shares of Eli Lilly and Company by 2.3% during the third quarter. Live Oak Private Wealth LLC now owns 1,809 shares of the company’s stock valued at $972,000 after purchasing an additional 40 shares during the period. Kingswood Wealth Advisors LLC grew its holdings in Eli Lilly and Company by 102.9% in the third quarter. Kingswood Wealth Advisors LLC now owns 3,907 shares of the company’s stock valued at $2,099,000 after purchasing an additional 1,981 shares during the period. Finally, Xponance Inc. boosted its stake in shares of Eli Lilly and Company by 0.3% during the 3rd quarter. Xponance Inc. now owns 189,291 shares of the company’s stock valued at $101,674,000 after purchasing an additional 590 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 0.6 %

Eli Lilly and Company stock traded down $4.35 during trading hours on Wednesday, hitting $776.75. The company had a trading volume of 2,762,706 shares, compared to its average volume of 3,067,439. Eli Lilly and Company has a 1 year low of $399.26 and a 1 year high of $800.78. The company has a 50-day moving average price of $761.41 and a two-hundred day moving average price of $669.21. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. The firm has a market cap of $738.04 billion, a P/E ratio of 133.47, a P/E/G ratio of 1.61 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Tuesday, April 30th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The firm had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. Eli Lilly and Company’s quarterly revenue was up 26.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.62 earnings per share. On average, sell-side analysts anticipate that Eli Lilly and Company will post 12.51 earnings per share for the current year.

Analyst Ratings Changes

LLY has been the topic of several research reports. BMO Capital Markets boosted their price objective on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an “outperform” rating in a research note on Wednesday. Bank of America upped their price target on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Citigroup boosted their price target on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a report on Tuesday, April 2nd. JPMorgan Chase & Co. increased their price target on Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a research note on Wednesday. Finally, Wells Fargo & Company lifted their price objective on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $742.95.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.